Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study
Our study suggests efgartigimod is an effective therapeutic option for JMG, with favorable efficacy and safety profiles. Further studies are necessary to validate the efficacy and safety of efgartigimod in the pediatric population.
Authors
- Yifan Zhang (ORCID: https://orcid.org/0000-0001-6488-6232)
- Zhijun Li (ORCID: https://orcid.org/0009-0009-4250-3427)
- Bitao Bu (ORCID: https://orcid.org/0000-0001-5369-7751)
- Ming Liu (ORCID: https://orcid.org/0000-0002-1114-1728)
- Meigui Han
- Zhilan Zhao
- Haoyou XU
- Xingjie Hao
- Qilong Jiang
- Junhong Yang
- Yuzhen Wei
- Lili Zhang
- Susan Luo
- Guoyan Qi
- Jing Lin
Institutions
- Qingdao University (CN)
- Guiyang Medical University (CN)
- Army Medical University (CN)
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- Daping Hospital (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- First Affiliated Hospital of Xinxiang Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- First Hospital of Shijiazhuang (CN)
- First Affiliated Hospital of Henan University of Traditional Chinese Medicine (CN)
- Huashan Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Henan Medical University (CN)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2026-03-07
- DOI
- https://doi.org/10.1002/mus.70202
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00